

FIRST HALF 2008 FINANCIAL INFORMATION

A CONFORTABLE LEVEL OF REVENUES

Paris, 12 August 2008 - Cegedim, the world's leading provider of CRM (Customer Relationship Management) solutions for the pharmaceutical industry, with 2008 half year revenues up to 25% with €418M, widely confirmed its 2008 revenues forecast and the success of Dendrite integration.

First half 2008 consolidated revenues (not audited)

Revenues (€ thousands)	2008	2007	Change	Gross change excluding sector impacts	2008 at constant consolidation scope and exchange rates (*)	2007 at constant consolidation scope and exchange rates (*)	Organic growth at constant exchange rates (*)
CRM and strategic data	240,094	186,178	29.0%	35,5%	250,860	177,877	41.0%
Healthcare professionals	125,085	94,000	33.1%	18,0%	129,088	94,000	37.3%
Insurance and services	52,593	52,962	-0.7%	5,9%	50,253	50,117	0.3%
Total revenues	417,772	333,140	25.4%		430,201	321,994	33.6%
First quarter	189,827	136,050	39.5%				
Second quarter	227,945	197,090	15.7%				

* Like-for-like growth is not restated for the activities of Dendrite, which were bought in May 2007 and whose impacts on the "CRM and strategic data" sector are no longer distinguishable due to intervening mergers.

New split of activities

In 2007, the activities sold to Tessi, which represented about one third of the "Technologies and services" sector, led to a more straightforward sector organization.

New split of the « Technologies and services » sector

Activities	New sectors	Comments
Direct marketing	CRM and strategic data	Activities mainly carried out with pharmaceutical industries
Cegelease	Healthcare professionals	Activities that are aimed at doctors and pharmacists
Cegedim SRH et PCO	Insurance and services	Activities completing our services and outsourcing offers

The growth of Cegedim Group activities offset the foreseen decrease of its American subsidiary during the first half year despite an unfavourable dollar rate.

The “**CRM and strategic data**” sector, which caters to pharmaceutical industries, increased its like-for-like revenues of 30% despite a negative change effect and the foreseen decrease of its American subsidiary during the first half year. Today, the international part of the revenues represents more than 72%, which clearly assert the Group as a worldwide player.

Activities in the “**Healthcare professionals**” sector cemented their momentum with an increase of more than 33% in comparison with the 2007 first half year. Like-for-like growth amounted to 18% excluding sector impacts and confirmed the steady progress of the medical and pharmaceutical software activities in France and in the United Kingdom. Moreover, the sustain growth came from the positive impact of the optimization of Cegelease contracts management.

In the “**Insurance and services**” sector, revenues from the Protectia acquisition offset, on the whole, the activities sold to Tessi. Excluding the impacts of the new sector organization, the growth amounted to 6% and complied with the growth generally established by this activity.

Half year highlights

The Group maintains its targeted acquisitions policy. After the February 2008 acquisition of Protectia in the field of personal insurance, Cegedim concluded the acquisition of the French entity “01 Santé” in April 2008. This acquisition gives the opportunities to Cegedim to extend its scope of activities in the healthcare software area.

First half 2008 financial situation and results

The trend in net debt is in line with projections made when Cegedim acquired Dendrite in May 2007.

Cegedim Group is maintaining its forecast for 2008 revenues in the range of €840M to €850M and projects an operating margin from ordinary operations on a par with 2007.

About Cegedim:

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, pharmaceutical companies, healthcare professionals and insurance companies.

The world leader in pharmaceutical CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs more than 8,000 people in 80 countries and generated revenue of €753 million in 2007.

To learn more, please visit our website: www.cegedim.com

Listed on NYSE Euronext Paris, compartiment B – ISIN FR0000053506 – Reuters CGDM.PA – Bloomberg CGM

Media inquiries

Cegedim

Aude Balleydier
Media Relations

Tel: + 33 (0)1 49 09 68 81
aude.balleydier@cegedim.fr

Presse & Papiers

Guillaume de Chamisso
Press Officer

Tel: + 33 (0)1 77 35 60 99
guillaume.dechamisso@pressepapiers.fr

Investor relations

Cegedim

Antoine Alazard
Tel: + 33 (0)1 49 09 86 41

Annelise Falandry
Tel: + 33 (0)1 49 09 31 94

Jan Eryk Umiastowski
Tel: + 33 (0)1 49 09 33 36

Investor.relations@cegedim.fr